Literature DB >> 24801647

A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer.

Barbara Banelli1, Anna Morabito1, Stefania Laurent2, Patrizia Piccioli3, Beatrice Dozin4, Massimo Ghio5, Paolo Antonio Ascierto6, Stefano Monteghirfo7, Antonella Marasco7, Vincenzo Ottaviano7, Paola Queirolo7, Massimo Romani1, Maria Pia Pistillo8.   

Abstract

CTLA-4 expression/function can be affected by single nucleotide polymorphisms (SNPs) of CTLA-4 gene, which have been widely associated with susceptibility or progression to autoimmune diseases and cancer development. In this study, we analyzed six CTLA-4 SNPs (-1661A>G, -1577G>A, -658C>T, -319C>T, +49A>G, CT60G>A) in 197 DNA samples from 43 B-lymphoblastoid cell lines (B-LCLs), 40 systemic sclerosis (SSc) patients, 14 pre-analyzed melanoma patients and 100 Italian healthy subjects. Genotyping of -1661A>G, -1577G>A, -658C>T and CT60G>A was performed by newly developed multiplex pyrosequencing (PSQ) assays, whereas -319C>T and +49A>G by T-ARMS PCR and direct sequencing. Genotype/allele frequency were analyzed using χ(2) or Fisher exact test. Our study provides the first multiplex PSQ method that allows simultaneous genotyping of two CTLA-4 SNP pairs (i.e. -1661A>G/-658C>T and -1577G>A/CT60G>A) by two multiplex PSQ reactions. Herein, we show the CTLA-4 genotype distribution in the B-LCLs providing the first and best characterized cell line panel typed for functionally relevant CTLA-4 SNPs. We also report the significant association of the -1661A/G genotype, -1661 & -319 AC-GT diplotype and -319 & CT60 TG haplotype with susceptibility to SSc without Hashimoto's thyroiditis occurrence. Furthermore, we confirmed previous genotyping data referred to melanoma patients and provided new genotyping data for Italian healthy subjects.
Copyright © 2014 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-LCLs; CTLA-4 single nucleotide polymorphisms; Melanoma patients; Pyrosequencing; Sclerodermic patients

Mesh:

Substances:

Year:  2014        PMID: 24801647     DOI: 10.1016/j.humimm.2014.04.019

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  4 in total

1.  Multiplex pyrosequencing assay using AdvISER-MH-PYRO algorithm: a case for rapid and cost-effective genotyping analysis of prostate cancer risk-associated SNPs.

Authors:  Jérôme Ambroise; Valentina Butoescu; Annie Robert; Bertrand Tombal; Jean-Luc Gala
Journal:  BMC Med Genet       Date:  2015-06-25       Impact factor: 2.103

2.  Role of CD152 genetic polymorphisms in the susceptibility to breast cancer.

Authors:  Hai Chen; Xiaodong Qi; Xue Bai; Ping Qiu; Bin Chen
Journal:  Oncotarget       Date:  2017-04-18

3.  Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Authors:  Paola Queirolo; Beatrice Dozin; Anna Morabito; Barbara Banelli; Patrizia Piccioli; Cristiana Fava; Claudio Leo; Roberta Carosio; Stefania Laurent; Vincenzo Fontana; Pier Francesco Ferrucci; Chiara Martinoli; Emilia Cocorocchio; Angelo Battaglia; Paolo A Ascierto; Mariaelena Capone; Ester Simeone; Federica De Galitiis; Elena Pagani; Gian Carlo Antonini Cappellini; Paolo Marchetti; Michele Guida; Stefania Tommasi; Mario Mandalà; Barbara Merelli; Pietro Quaglino; Paolo Fava; Massimo Guidoboni; Massimo Romani; Francesco Spagnolo; Maria Pia Pistillo
Journal:  Front Immunol       Date:  2017-04-12       Impact factor: 7.561

4.  Molecular alterations in the TCR signaling pathway in patients with aplastic anemia.

Authors:  Bo Li; Lixing Guo; Yuping Zhang; Yankai Xiao; Mingjuan Wu; Lingling Zhou; Shaohua Chen; Lijian Yang; Xiang Lu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2016-03-31       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.